Vor Bio Grants Stock Options and Restricted Stock Units to New Employees as Part of Inducement Plan

Vor Bio granted stock options and RSUs to 20 new employees as inducements for employment, adhering to Nasdaq regulations.

Quiver AI Summary

Vor Bio, a biotechnology company focused on treating autoimmune diseases, announced the grant of stock options and restricted stock units (RSUs) to 20 new employees on October 15, 2025. The total includes stock options to purchase 113,478 shares and RSUs representing 24,319 shares, intended as incentives for employment in accordance with Nasdaq regulations. The options have a ten-year term with an exercise price of $30.22 per share, vesting over four years, while the RSUs also vest over four years with a similar schedule. Vor Bio is currently advancing its lead product, telitacicept, through Phase 3 clinical trials.

Potential Positives

Granting stock options and RSUs to newly hired employees demonstrates Vor Bio's commitment to attracting talent, which can enhance its research and development capabilities.
The stock options have a ten-year term and are tied to the company's performance, aligning the interests of employees with those of shareholders.
The focus on telitacicept and its advancement through Phase 3 clinical development highlights Vor Bio's dedication to addressing significant medical needs in autoimmune diseases, potentially leading to meaningful market opportunities.
The issuance of stock options and RSUs aligns with Nasdaq Listing Rule 5635(c)(4), ensuring compliance with regulatory standards, which can enhance investor confidence.

Potential Negatives

The issuance of stock options and RSUs, while intended to attract talent, may signal a high turnover rate or difficulty in hiring, reflecting negatively on the company's stability and work environment.
The reliance on stock-based compensation as a material inducement could imply challenges in offering competitive cash salaries, which may affect employee satisfaction and retention in the long run.
Granting a significant number of stock options and RSUs to new employees could raise concerns among investors about potential dilution of existing shares and impact on shareholder value.

FAQ

What recent stock options were granted by Vor Bio?

Vor Bio granted stock options to purchase 113,478 shares of common stock to 20 new employees on October 15, 2025.

What are the vesting terms for the stock options?

The stock options vest over four years, with 25% vesting after 12 months and the rest monthly over the next 36 months.

What is the exercise price for the stock options?

The exercise price for the stock options is $30.22 per share, equal to the closing price on the grant date.

What is the purpose of the stock options and RSUs?

The stock options and RSUs were granted as material inducements to employment with Vor Bio under the Inducement Plan.

What does Vor Bio focus on in its research?

Vor Bio focuses on transforming treatment for autoimmune diseases, specifically advancing their novel dual-target fusion protein, telitacicept.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$VOR Insider Trading Activity

$VOR insiders have traded $VOR stock on the open market 70 times in the past 6 months. Of those trades, 0 have been purchases and 70 have been sales.

Here’s a breakdown of recent trading of $VOR stock by insiders over the last 6 months:

CAPITAL MANAGEMENT, L.P. RA has made 0 purchases and 28 sales selling 1,202,649 shares for an estimated $33,715,154.
INTERCHANGE LLC REPROGRAMMED has made 0 purchases and 42 sales selling 6,665,043 shares for an estimated $27,680,032.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$VOR Hedge Fund Activity

We have seen 16 institutional investors add shares of $VOR stock to their portfolio, and 27 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC removed 4,329,810 shares (-67.4%) from their portfolio in Q2 2025, for an estimated $7,014,292
UBS GROUP AG added 1,523,181 shares (+18015.2%) to their portfolio in Q2 2025, for an estimated $2,467,553
HRT FINANCIAL LP added 474,575 shares (+inf%) to their portfolio in Q2 2025, for an estimated $768,811
SCIENTECH RESEARCH LLC added 403,859 shares (+inf%) to their portfolio in Q2 2025, for an estimated $654,251
SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 384,293 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $622,554
JANE STREET GROUP, LLC added 330,857 shares (+169.9%) to their portfolio in Q2 2025, for an estimated $535,988
MAI CAPITAL MANAGEMENT removed 284,711 shares (-98.7%) from their portfolio in Q2 2025, for an estimated $461,231

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$VOR Analyst Ratings

Wall Street analysts have issued reports on $VOR in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 10/29/2025

To track analyst ratings and price targets for $VOR, check out Quiver Quantitative's $VOR forecast page.

$VOR Price Targets

Multiple analysts have issued price targets for $VOR recently. We have seen 4 analysts offer price targets for $VOR in the last 6 months, with a median target of $29.0.

Here are some recent targets:

Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $52.0 on 10/29/2025
Jack Allen from Baird set a target price of $64.0 on 10/15/2025
David Nierengarten from Wedbush set a target price of $0.4 on 06/26/2025
Silvan Tuerkcan from JMP Securities set a target price of $6.0 on 05/09/2025

Full Release

BOSTON, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 15, 2025, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 113,478 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 24,319 shares of Vor Bio’s common stock to 20 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

The stock options have a ten-year term, and the exercise price is $30.22 per share, which is equal to the closing price of Vor Bio’s common stock on the grant date of the stock options and RSUs. The options will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The RSUs will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting quarterly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The options and RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an award agreement covering the grants.

About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com .

Media & Investor Contacts:
Carl Mauch
[email protected]

Sarah Spencer
[email protected]